Impact Where It Matters

Celligenics is proud to announce the publication of our latest scientific breakthrough: "Development and functional testing of a novel in vitro delayed scratch closure assay" in the Springer Nature journal, Histochemistry and Cell Biology.

Celligenics is pleased to announce that we have signed a memorandum of understanding with West China Hospital (Hua Xi) of Sichuan University at the 22nd Singapore-Sichuan Trade and Investment Committee Meeting.

Celligenics is pleased to unveil its first corporate video, titled Enabling Cellular Therapeutics. The video introduces our research team and showcases our research facility, reiterating our endeavour to achieve our vision and mission in providing accessible and affordable healthcare solutions for everyone.

Celligenics is pleased to announce that we have signed a Memorandum of Understanding (MOU) with our Series A investor, Best World International (BWI)

Celligenics visited Changi General Hospital (CGH)'s Wound Care Clinic with the Skin Research Institute of Singapore (SRIS) yesterday, and would like to thank the doctors, nurses, and staff for hosting us at their world-class wound care treatment facilities, and sharing their invaluable insights in caring for patients with chronic wounds.

Celligenics is honoured to have participated in a dialogue session comprising industry representatives from local biotech, venture capital, and big pharma yesterday with Dr. Tan See Leng, Minister in the Prime Minister’s Office, Second Minister for Trade and Industry and Second Minister for Manpower

Celligenics is proud to announce that we will be participating in the Singapore Week of Innovation and Technology (SWITCH) for our third consecutive year.

Celligenics is proud to have participated in the Singapore Week of Innovation and Technology (SWITCH) for our second consecutive year.

Celligenics is pleased to announce the appointment of Dr. Pauline Tay as Chief Operating Officer. Dr. Tay joins us from the National Research Foundation (NRF), where she serves as Senior Deputy Director of Innovation and Enterprise Strategy.

Celligenics is pleased to announce the close of our Series A fundraising exercise, raising $5.6 Mio, with Best World International (BWI) taking up at least a 12.5 per cent stake in our company.